Sublingual allergy tablet launches in Canada; Elixir demonstrates new stent;

> ALK's ragweed sublingual allergy immunotherapy tablet, licensed to Merck ($MRK), just launched in Canada. Release

> Elixir Medical successfully demonstrated its DESolve 100 bioresorbable stent at the EuroPCR conference in Paris. Release

> Stanford researchers are developing small implants to be placed deep inside the body. These machines could someday replace pain medications, the scientists say. Story

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.